Literature DB >> 3709612

Pharmacokinetics of tenoxicam in patients with impaired renal function.

F F Horber, T W Guentert, E Weidekamm, P Heizmann, C Descoeudres, F J Frey.   

Abstract

The pharmacokinetics of tenoxicam after a single oral dose of 20 mg has been studied in 12 patients with various degrees of decreased renal function. Unchanged tenoxicam and its 5'OH-metabolite in plasma and urine were determined by HPLC. The mean areas under the plasma concentration-time curve (138 +/- 53 micrograms/ml X h) and terminal half-lives in patients with impaired renal function did not differ from values previously reported in normal volunteers, nor did the peak concentration of tenoxicam. The half-life of 5'OH-tenoxicam and unchanged tenoxicam where the same. The urinary excretion of 5'OH-tenoxicam fell with decreasing renal function. Thus no dosage adjustment should be necessary and the usual daily dose of tenoxicam may be administered once daily also to patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3709612     DOI: 10.1007/bf00615961

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Enzyme induction in the uremic liver.

Authors:  H W Leber; L Gleumes; G Schütterle
Journal:  Kidney Int Suppl       Date:  1978-06       Impact factor: 10.545

2.  [Pharmacokinetics of indomethacin in patients with kidney lesions].

Authors:  A Traeger; G Stein; M Kunze; J Zaumseil
Journal:  Int J Clin Pharmacol       Date:  1972-08

3.  Impaired renal function and hypercalcaemia associated with etretinate.

Authors:  F F Horber; A Zimmermann; F J Frey
Journal:  Lancet       Date:  1984-11-10       Impact factor: 79.321

4.  Pharmacokinetics of isoxicam in man following oral administration.

Authors:  E U Kölle; H Hengy; K O Vollmer
Journal:  Arzneimittelforschung       Date:  1983

5.  Determination of the hepatic elimination capacity (Lm) of galactose by single injection.

Authors:  N Tygstrup
Journal:  Scand J Clin Lab Invest Suppl       Date:  1966

6.  Pharmacokinetics of fenbufen in man.

Authors:  G Cuisinaud; J Legheand; G Llorca; C Belkahia; E Lejeune; J Sassard
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

7.  Determination of tenoxicam, and the isolation, identification and determination of Ro 17-6661, its major metabolite, in human urine.

Authors:  D Dell; R Joly; W Meister; W Arnold; C Partos; B Guldimann
Journal:  J Chromatogr       Date:  1984-12-28

8.  Pharmacokinetics of ketoprofen in patients with chronic renal failure.

Authors:  G Stafanger; H W Larsen; H Hansen
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

9.  [Inter- and intra-individual variations on the disposition of piroxicam. Pharmacokinetics in healthy man and the patient with renal insufficiency].

Authors:  D Dupont; P Dayer; L Balant; A Gorgia; J Fabre
Journal:  Pharm Acta Helv       Date:  1982

10.  Kinetics of single doses of fenbufen in patients with renal insufficiency.

Authors:  H J Rogers; J P Savitsky; B Glenn; R G Spector
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

View more
  10 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Plasma tenoxicam concentrations after single and multiple oral doses.

Authors:  C Crevoisier; P Heizmann; I Forgo; U C Dubach
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Jan-Mar       Impact factor: 2.441

Review 3.  Tenoxicam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  J P Gonzalez; P A Todd
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 4.  Tenoxicam. An update of its pharmacology and therapeutic efficacy in rheumatic diseases.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

5.  Pharmacokinetic-Pharmacodynamic Modelling of the antipyretic effect of two oral formulations of ibuprofen.

Authors:  I F Trocóniz; S Armenteros; M V Planelles; J Benítez; R Calvo; R Domínguez
Journal:  Clin Pharmacokinet       Date:  2000-06       Impact factor: 6.447

6.  Single and multiple dose pharmacokinetics of tenoxicam in the elderly.

Authors:  O G Nilsen; R A Walstad; M Eckert; P Heizmann; A Bückert; T Am; I Løge; J Unnvik; E Thue
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.

Authors:  K T Olkkola; A V Brunetto; M J Mattila
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

8.  The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.

Authors:  M S al-Ghamdi; F A al-Mohanna; Z H al-Mustafa; I S al-Saeed
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  An assessment of tenoxicam, a nonsteroidal anti-inflammatory drug of long half-life, in patients with impaired renal function suffering from osteoarthritis or rheumatoid arthritis.

Authors:  H A Bird; A K Clarke; P D Fowler; S Little; M R Podgorski; J Steiner
Journal:  Clin Rheumatol       Date:  1989-12       Impact factor: 2.980

Review 10.  Clinical pharmacokinetics of tenoxicam.

Authors:  O G Nilsen
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.